RU2416613C2 - Производные эрголина и их применение в качестве лигандов хемокинного рецептора - Google Patents

Производные эрголина и их применение в качестве лигандов хемокинного рецептора Download PDF

Info

Publication number
RU2416613C2
RU2416613C2 RU2007147597/04A RU2007147597A RU2416613C2 RU 2416613 C2 RU2416613 C2 RU 2416613C2 RU 2007147597/04 A RU2007147597/04 A RU 2007147597/04A RU 2007147597 A RU2007147597 A RU 2007147597A RU 2416613 C2 RU2416613 C2 RU 2416613C2
Authority
RU
Russia
Prior art keywords
formula
optionally
alkyl
substituted
pharmaceutically acceptable
Prior art date
Application number
RU2007147597/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007147597A (ru
Inventor
Рольф БЭНТЕЛИ (CH)
Рольф Бэнтели
Фрейзер ГЛИКМАН (CH)
Фрейзер ГЛИКМАН
Иржи КОВАРИК (CH)
Иржи КОВАРИК
Айан ЛУИС (CH)
Айан ЛУИС
Маркус ШТРАЙФФ (CH)
Маркус ШТРАЙФФ
Гебхард ТОМА (DE)
Гебхард Тома
Ханс-Гюнтер ЦЕРВЕС (DE)
Ханс-Гюнтер ЦЕРВЕС
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2007147597A publication Critical patent/RU2007147597A/ru
Application granted granted Critical
Publication of RU2416613C2 publication Critical patent/RU2416613C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
RU2007147597/04A 2005-05-31 2006-05-29 Производные эрголина и их применение в качестве лигандов хемокинного рецептора RU2416613C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0511060.6A GB0511060D0 (en) 2005-05-31 2005-05-31 Organic compounds
GB0511060.6 2005-05-31

Publications (2)

Publication Number Publication Date
RU2007147597A RU2007147597A (ru) 2009-07-20
RU2416613C2 true RU2416613C2 (ru) 2011-04-20

Family

ID=34834898

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007147597/04A RU2416613C2 (ru) 2005-05-31 2006-05-29 Производные эрголина и их применение в качестве лигандов хемокинного рецептора

Country Status (12)

Country Link
US (1) US7666877B2 (https=)
EP (1) EP1893611A1 (https=)
JP (1) JP5121703B2 (https=)
KR (1) KR20080013971A (https=)
CN (1) CN101184754B (https=)
AU (1) AU2006254395B2 (https=)
BR (1) BRPI0611489A2 (https=)
CA (1) CA2608702C (https=)
GB (1) GB0511060D0 (https=)
MX (1) MX2007015084A (https=)
RU (1) RU2416613C2 (https=)
WO (1) WO2006128658A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN04858A (https=) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
US9095591B2 (en) 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
RU2014153672A (ru) * 2012-06-22 2016-08-10 Мап Фармасьютикалс, Инк. Новые каберголиновые производные
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070921A1 (en) 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAKAHARA Y. et al. // Chemical and Pharm. Bull. v 19, №11, p.2337-2341. *

Also Published As

Publication number Publication date
EP1893611A1 (en) 2008-03-05
JP5121703B2 (ja) 2013-01-16
CN101184754B (zh) 2010-12-22
BRPI0611489A2 (pt) 2010-11-23
AU2006254395A1 (en) 2006-12-07
WO2006128658A1 (en) 2006-12-07
US20090018127A1 (en) 2009-01-15
US7666877B2 (en) 2010-02-23
CN101184754A (zh) 2008-05-21
RU2007147597A (ru) 2009-07-20
AU2006254395B2 (en) 2010-09-09
CA2608702C (en) 2013-10-15
GB0511060D0 (en) 2005-07-06
CA2608702A1 (en) 2006-12-07
JP2008545725A (ja) 2008-12-18
KR20080013971A (ko) 2008-02-13
MX2007015084A (es) 2008-01-17

Similar Documents

Publication Publication Date Title
RU2416613C2 (ru) Производные эрголина и их применение в качестве лигандов хемокинного рецептора
JP6850922B2 (ja) Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
KR100616039B1 (ko) 비피페리디닐-유도체 및 이의 케모킨 수용체 억제제로서의 용도
US9676713B2 (en) Crystal of pyrrole derivative and method for producing the same
CN111138448A (zh) 抑制rip1激酶的杂环酰胺及其用途
RU2591190C2 (ru) Новые 4-амино-n-гидроксибензамиды в качестве ингибиторов hdac для лечения рака
JPH06504042A (ja) 置換ベンゾフラン誘導体の製造法
AU2017274110B2 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
NO316754B1 (no) Indolylpyrrolydenmetylpyrrolderivater, farmasoytisk preparat inneholdende slike derivater, deres anvendelse, og fremgangsmater for deres fremstilling
US5519025A (en) 4-indolylpiperazinyl derivatives
JPS62187452A (ja) 環状アミン誘導体
US20040067959A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists
CZ248394A3 (en) Novel derivatives of perhydroisoindole and process of their preparation
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
WO2008051440A1 (en) Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-d ione
RU2101284C1 (ru) Оптически активные производные карбоксамидов или их фармакологически пригодные соли, фармацевтическая композиция, обладающая анальгезирующей активностью
WO2024081961A2 (en) Ester analogs of psilocin, processes for the preparation thereof, and methods of use
RU2024516C1 (ru) Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
CY1432A (en) Ergotalkaloids
EP0434621A2 (en) Rifamycin derivatives and processes for the manufacture thereof
CA2011172A1 (en) Acyl derivatives
JPH02138172A (ja) β−アミノ酸アミド誘導体
EA047316B1 (ru) Способ синтеза фуроимидазопиридинового соединения, кристаллическая форма фуроимидазопиридинового соединения и кристаллическая форма его соли
HK1241358B (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
GB2075973A (en) Indoloquinolizines

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140530